Dr. John Cush RheumNow
3 years 5 months ago
British Society of Rheumatology Plans Revision of Systemic Sclerosis Guideline
BSR last published its guideline for SSc in 2016. Given the many advances in the field the BSR has outlined their plans to update the management of SSc.
https://t.co/s4AKdVS2H7 https://t.co/MmIGw2QLEn
Dr. John Cush RheumNow
3 years 5 months ago
Inflammasome inhibitors in development:
- RRx-001 in cancer, ALS, parkinsons
- OLT1177 in OA knee, gout, Schnitzlers
- DFV890 in CAPs, knee OA
- IZD174/334 in CAPS
- ZYIL1 CAPS
https://t.co/1oCmKIHchP https://t.co/Y8CBAx2T7w
Dr. John Cush RheumNow
3 years 5 months ago
New downlaod available: Gender Risk in Rheumatic Disease
https://t.co/5AQhSNzrvh https://t.co/wTGnCk7ctj
Dr. John Cush RheumNow
3 years 5 months ago
EMA Final Update on JAK Inhibitors and MACE, Malignancy & VTE Risks
https://t.co/k4UZZtyvdf https://t.co/ZI3NMw7Iec
Dr. John Cush RheumNow
3 years 5 months ago
Paxlovid (Nirmatrelvir-Ritonavir) should be used w/in 5d of COVID Sxs onset. Drug interactions include: steroids, anticoagulants (Eliquis, Xarelto, warfarin), Flomax, Calcium channel blockers, benzodiazepines. https://t.co/FmjeWvWo58 https://t.co/BaKwun23pD
Dr. John Cush RheumNow
3 years 5 months ago
Frunevetmab (Solensia), is a cat-specific mAb against nerve growth factor was FDA approved, for use in CATS, to treat the pain of osteoarthritis. CATS! https://t.co/OFb0vtndf1 https://t.co/14g2Fzeh2i
Dr. John Cush RheumNow
3 years 5 months ago
DESIR - early SpA Cohort study of 494 pts (half F); w/ 6 yrs F/U, Women had higher ASDAS-CRP & PtGA (P < 0.0001; vs men), yet CRP was similar and structural damage more frequent in men (P < 0.0001). https://t.co/cxehQuEOtu https://t.co/6PwtjEgLDD
Dr. John Cush RheumNow
3 years 5 months ago
RheumThoughts: Changing the Conversation with Patients: Lupus
https://t.co/rFM2211Toq https://t.co/I9yWGMCH9B
Dr. John Cush RheumNow
3 years 5 months ago
AMA survey shows 94% MD report delays in Pt care assoc w/ prior authorization. MDs spend 2d/wk on PA &1/3 hire added staff for PA. 4/5 PAs result in abandoned Rx. CMC has a proposed rule to speed up PA approval. Congress needs to act on this PA problem! https://t.co/XNtlk5TzX5 https://t.co/QtzXQLyjWD
During the week of April 3, 2023, registered Rheumatologists responded to an email survey regarding work-life balance. The following are the results from 190 respondents - 53% were male (47% female) and 94% were from the USA.
Question 1. Do you frequently miss significant life events due to work obligations?
Dr. Jack Cush reviews the news and highlights from our "Women in Rheumatology" Campaign from last week on RheumNow.com
Dr. John Cush RheumNow
3 years 5 months ago
Steroid-Sparing Rituximab in Polymyalgia Rheumatica
https://t.co/FDvVSFnuDf https://t.co/s6B2AZrv1T
Dr. John Cush RheumNow
3 years 5 months ago
Dutch Biologic Monitor surveys of RA, PsA, axSpA pts on etanercept or adalimumab, looked at adverse drug reactions. Among 748 consecutive pts on biologics, women had more ADRs (55%) than men (38%). nature ofreported ADRs differed betw sexes (p = 0.02). https://t.co/fGRgX4IJLR https://t.co/FJE7BrKPfQ
Dr. John Cush RheumNow
3 years 5 months ago
Our next Tuesday Night Rheumatology addresses Contract Negotiations, featuring Andrea Liberatore, JD, Gwenesta Melton, MD, and Kathryn Dao, MD.
Sign up to attend this and all of our Tuesday Night Rheumatology series.
@uptoTate @KDAO2011
https://t.co/OuUnPnknQT https://t.co/fpNgGsnmb7
